Jeong YM, Duanting Z, Hennig H, et al. CDy6, a photostable probe for long-term real-time visualization of mitosis and proliferating cells. Chem Biol. 2015;22(2):299-307. doi:10.1016/j.chembiol.2014.11.018
Jalili A, Wagner C, Pashenkov M, et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012;104(21):1673-9. doi:10.1093/jnci/djs373
Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun. 2015;6:6517. doi:10.1038/ncomms7517
Quayle SN, Chheda MG, Shukla SA, et al. Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012;14(11):1325-31. doi:10.1093/neuonc/nos246
Hsieh CL, Botta G, Gao S, et al. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015;75(10):1944-8. doi:10.1158/0008-5472.CAN-14-3602
Birsoy K, Wang T, Possemato R, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet. 2013;45(1):104-8. doi:10.1038/ng.2471
Danino T, Prindle A, Kwong GA, et al. Programmable probiotics for detection of cancer in urine. Sci Transl Med. 2015;7(289):289ra84. doi:10.1126/scitranslmed.aaa3519
Rosenbluh J, Nijhawan D, Cox AG, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-73. doi:10.1016/j.cell.2012.11.026
Hiraki M, Hwang SY, Cao S, et al. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem Biol. 2015;22(9):1206-16. doi:10.1016/j.chembiol.2015.07.016